|
|
|
Insider
Information: |
Conterno Enrique A |
Relationship: |
Chief Executive Office... |
City: |
Indianapolis |
State: |
IN |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
2 |
|
Direct
Shares |
507,684 |
|
Indirect Shares
|
32,959 |
|
|
Direct
Value |
$102,830,406 |
|
|
Indirect Value
|
$4,005,790 |
|
|
Total
Shares |
540,643 |
|
|
Total
Value |
$106,836,196 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
2
|
7
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
2
|
7
|
|
|
|
Gain/Loss Ratio : |
-2.0
|
-7.0
|
Percentage
Gain/Loss : |
-5.7%
|
-569.9%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Eli Lilly & Co |
LLY |
SVP&Pres, LillyDiab & ... |
2019-02-15 |
132,962 |
2019-02-15 |
5,159 |
Premium* |
|
Fibrogen Inc |
FGEN |
Chief Executive Office... |
2023-07-07 |
374,722 |
2023-07-07 |
27,800 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
80 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 4
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
LLY |
Eli Lilly & Co |
Sr. VP, Diabetes Business Unit |
|
2009-11-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
9,392 |
|
- |
|
LLY |
Eli Lilly & Co |
Sr. VP, Diabetes Business Unit |
|
2009-11-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,919 |
|
- |
|
FGEN |
Fibrogen Inc |
Chief Executive Officer |
|
2022-07-06 |
4 |
D |
$12.40 |
$16,070 |
D/D |
(1,296) |
302,631 |
0 |
- |
|
FGEN |
Fibrogen Inc |
Chief Executive Officer |
|
2022-10-06 |
4 |
D |
$14.26 |
$18,481 |
D/D |
(1,296) |
299,563 |
0 |
- |
|
FGEN |
Fibrogen Inc |
Chief Executive Officer |
|
2022-04-07 |
4 |
D |
$12.73 |
$16,689 |
D/D |
(1,311) |
303,712 |
0 |
- |
|
FGEN |
Fibrogen Inc |
Chief Executive Officer |
|
2022-01-06 |
4 |
D |
$13.93 |
$21,396 |
D/D |
(1,536) |
132,704 |
0 |
- |
|
FGEN |
Fibrogen Inc |
Chief Executive Officer |
|
2023-01-06 |
4 |
S |
$19.95 |
$30,683 |
D/D |
(1,538) |
295,483 |
0 |
% |
|
FGEN |
Fibrogen Inc |
Chief Executive Officer |
|
2022-06-06 |
4 |
D |
$9.50 |
$16,834 |
D/D |
(1,772) |
301,940 |
0 |
- |
|
FGEN |
Fibrogen Inc |
Chief Executive Officer |
|
2022-09-06 |
4 |
D |
$12.26 |
$21,725 |
D/D |
(1,772) |
300,859 |
0 |
- |
|
FGEN |
Fibrogen Inc |
Chief Executive Officer |
|
2021-07-06 |
4 |
D |
$25.06 |
$46,587 |
D/D |
(1,859) |
136,098 |
0 |
- |
|
FGEN |
Fibrogen Inc |
Chief Executive Officer |
|
2021-10-06 |
4 |
D |
$10.20 |
$18,962 |
D/D |
(1,859) |
134,239 |
0 |
- |
|
FGEN |
Fibrogen Inc |
Chief Executive Officer |
|
2023-04-10 |
4 |
S |
$19.52 |
$36,483 |
D/D |
(1,869) |
382,999 |
0 |
% |
|
FGEN |
Fibrogen Inc |
Chief Executive Officer |
|
2023-07-07 |
4 |
S |
$2.80 |
$5,264 |
D/D |
(1,880) |
374,722 |
0 |
% |
|
LLY |
Eli Lilly & Co |
Sr. VP & Pres., Lilly Diabetes |
|
2010-10-18 |
4 |
D |
$37.76 |
$93,985 |
D/D |
(2,489) |
25,238 |
0 |
- |
|
FGEN |
Fibrogen Inc |
Chief Executive Officer |
|
2022-12-08 |
4 |
S |
$15.79 |
$40,154 |
D/D |
(2,543) |
297,020 |
0 |
% |
|
LLY |
Eli Lilly & Co |
Sr. VP & Pres., Lilly Diabetes |
|
2013-05-01 |
4 |
D |
$55.38 |
$260,175 |
D/D |
(4,698) |
77,177 |
0 |
- |
|
LLY |
Eli Lilly & Co |
Sr. VP & Pres., Lilly Diabetes |
|
2017-02-01 |
4 |
D |
$77.03 |
$370,514 |
D/D |
(4,810) |
139,217 |
0 |
- |
|
LLY |
Eli Lilly & Co |
Sr. VP & Pres., Lilly Diabetes |
|
2016-02-01 |
4 |
D |
$79.10 |
$385,375 |
D/D |
(4,872) |
113,572 |
0 |
- |
|
LLY |
Eli Lilly & Co |
Sr. VP & Pres., Lilly Diabetes |
|
2012-04-02 |
4 |
AS |
$40.30 |
$201,500 |
D/D |
(5,000) |
47,012 |
0 |
- |
|
LLY |
Eli Lilly & Co |
Sr. VP & Pres., Lilly Diabetes |
|
2012-05-01 |
4 |
AS |
$41.32 |
$206,600 |
D/D |
(5,000) |
42,012 |
0 |
- |
|
LLY |
Eli Lilly & Co |
Sr. VP & Pres., Lilly Diabetes |
|
2012-06-01 |
4 |
AS |
$40.60 |
$203,000 |
D/D |
(5,000) |
37,012 |
0 |
- |
|
LLY |
Eli Lilly & Co |
Sr. VP & Pres., Lilly Diabetes |
|
2012-07-02 |
4 |
AS |
$43.00 |
$215,000 |
D/D |
(5,000) |
32,012 |
0 |
- |
|
LLY |
Eli Lilly & Co |
Sr. VP & Pres., Lilly Diabetes |
|
2012-08-01 |
4 |
AS |
$44.16 |
$220,800 |
D/D |
(5,000) |
27,012 |
0 |
- |
|
LLY |
Eli Lilly & Co |
Sr. VP & Pres., Lilly Diabetes |
|
2013-04-15 |
4 |
AS |
$57.10 |
$285,500 |
D/D |
(5,000) |
71,875 |
0 |
- |
|
LLY |
Eli Lilly & Co |
Sr. VP & Pres., Lilly Diabetes |
|
2013-05-15 |
4 |
AS |
$56.15 |
$280,750 |
D/D |
(5,000) |
72,177 |
0 |
- |
|
80 Records found
|
|
Page 1 of 4 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|